# Provisional Authorisation for COVID-19 Tests

| | |
|---|---|
| *Applicant* | Siemens Healthcare Pte Ltd |
| *Name of test* | Atellica® IM SARS-CoV-2 Antigen (CoV2Ag) |
| *Intended purpose (As per manufacturer's information for use)* | *The Atellica® IM SARS-CoV-2 Antigen (CoV2Ag) assay is for in vitro diagnostic use in the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal (NP) swab and anterior nasal (AN) swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset, or from asymptomatic individuals, using an Atellica® immunoassay analyzer.*<br><br>*This assay is intended as an aid in the diagnosis of patients with suspected SARS-CoV-2 infection.* |
| *Date of Provisional Authorisation* | 29 March 2021 |